Consensus Arcus Biosciences, Inc.

Stocks

RCUS

US03969F1093

Biotechnology & Medical Research

Market Closed - NYSE 01:30:03 16/09/2026 am IST			5-day change	1st Jan Change
24.32 ^USD	+1.04%		-16.31%	+2.06%

11:05pm	Arcus Biosciences, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 12:20 PM
09/09	Arcus Biosciences, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10:40 AM

Evolution of the Average Target: Arcus Biosciences, Inc.

Evolution of the Target Price: Arcus Biosciences, Inc.

Changes in Analyst Recommendations: Arcus Biosciences, Inc.

9123f5566a7d0d248238dc359b7307.XZNZd4v6_y-ESKJ6A3MPebrVx-peQmSHEkXuErMD5iI.ass0FuiWmHntfJZKSik2TfKAiYgPJRfvfh-rYYsxvBVsp3Q8vJSLYeA_1Q~5635ca61d07fbf40b24c5991cf70dcef

Analysts' recommendations: Arcus Biosciences, Inc.

10/08	Arcus Biosciences' Casdatifan Therapy Could be Launched in 2028, Morgan Stanley Says	MT
10/08	Morgan Stanley Adjusts Price Target on Arcus Biosciences to $23 From $22, Maintains Equalweight Rating	MT
06/08	Wedbush Adjusts Price Target on Arcus Biosciences to $43 From $41, Maintains Outperform Rating	MT
03/08	BofA Securities Adjusts Arcus Biosciences Price Target to $29 From $25	MT
21/04	Arcus Biosciences Has Favorable Setup After Merck Belzutifan Failure, Wedbush Says	MT
02/04	Wedbush Raises Price Target on Arcus Biosciences to $41 From $37, Keeps Outperform Rating, Adds Stock to Best Ideas List	MT
12/02	Wells Fargo Downgrades Arcus Biosciences to Equal Weight From Overweight, Adjusts PT to $23 From $30	MT
08/01	Morgan Stanley Downgrades Arcus Biosciences to Equal Weight From Overweight, Cuts Price Target to $20 From $23	MT
12/12	Wedbush Adjusts Arcus Biosciences Price Target to $37 From $35, Maintains Outperform Rating	MT
12/12	Truist Securities Adjusts Arcus Biosciences Price Target to $30 From $39, Maintains Buy Rating	MT
03/11	Mizuho Raises Price Target on Arcus Biosciences to $47 From $45, Keeps Outperform Rating	MT
29/25/29	Wedbush Raises Price Target on Arcus Biosciences to $35 From $33, Keeps Outperform Rating	MT
14/25/14	Arcus Biosciences, Inc. Announces First Overall Survival Results from Arm A1 of the Phase 2 EDGE-Gastric Study	CI
07/25/07	Truist Raises Price Target on Arcus Biosciences to $39 From $32, Keeps Buy Rating	MT
18/25/18	Mizuho Raises Price Target on Arcus Biosciences to $45 From $42, Keeps Outperform Rating	MT
07/25/07	Morgan Stanley Lifts Price Target on Arcus Biosciences to $23 From $22, Keeps Overweight Rating	MT
07/25/07	Arcus Biosciences Q2 revenue beats analyst expectations	RE
09/25/09	Morgan Stanley Lowers Price Target on Arcus Biosciences to $22 From $24, Keeps Overweight Rating	MT
26/25/26	HC Wainwright Upgrades Arcus Biosciences to Buy From Neutral, Adjusts Price Target to $24 From $18	MT
19/25/19	Wedbush Cuts Arcus Biosciences' Price Target to $33 From $36, Keeps Outperform Rating	MT
21/24/21	HC Wainwright Initiates Coverage on Arcus Biosciences With Neutral Rating, $20 Price Target	MT
08/24/08	Wells Fargo Initiates Arcus Biosciences at Overweight With $29 Price Target	MT
24/24/24	Truist Lowers Price Target on Arcus Biosciences to $44 From $50, Maintains Buy Rating	MT
03/24/03	Citigroup Adjusts Arcus Biosciences Price Target to $38 From $36, Maintains Buy Rating	MT
30/24/30	Mizuho Adjusts Arcus Biosciences' Price Target to $42 From $51, Keeps Buy Rating	MT

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ARCUS BIOSCIENCES, INC.					+60.99%
	LONZA GROUP AG					+28.82%
	REVOLUTION MEDICINES, INC.					+22.48%
	IQVIA HOLDINGS INC.					+3.99%
	BEONE MEDICINES AG					+22.32%
	CELLTRION, INC.					+50.02%
	ASCENDIS PHARMA A/S					+17.93%
	MEDPACE HOLDINGS, INC.					-2.28%
	EUROFINS SCIENTIFIC SE					+0.11%
	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.					+3.41%
	Average					+20.78%
	Weighted average by Cap.					+20.28%